Exhibit 99.1 Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress CAMBRIDGE, Mass., May 8, 2025 – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today reported operational highlights and financial results for the first quarter ended March 31, 2025. "Intellia is full steam ahead and making excellent progress across its clinical programs," said Intel ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Enrollment in the global Phase 3 MAGNITUDE trial of nex-z in patients with ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projectionsPresenting additional data from the Phase 1 portion of the ongo ...

Intellia Therapeutics, Inc. (NTLA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, NTLA broke out above the 50-day moving average, suggesting a short-term bullish trend.One of the three major moving averages, the 50-day simple moving average is commonly used by traders and analysts to determine support or resistance levels for different types of securities. However, the 50-day is considered to be more important since it's the first m ...

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its first quarter 2025 financial results and operational highlights in a conference call on May 8, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants sh ...

Intellia Therapeutics, Inc. (NTLA) closed the last trading session at $8.48, gaining 19.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $41.79 indicates a 392.8% upside potential.The mean estimate comprises 24 short-term price targets with a standard deviation of $27.61. While the lowest estimate of $9 indicates a 6.1% increase from the current price level, the most optimistic a ...

SAN DIEGO, April 23, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA).Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) prior to July 2024 and continue to hold any of thoseNASDAQ: NTLA shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.On February 11, 2025, aNASDAQ: NTLA investor filed a lawsuit ag ...

LOS ANGELES, April 14, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Intellia Therapeutics ("Intellia" or "the Company") (NASDAQ: NTLA) for violations of the federal securities laws.Shareholders who purchased the Company's securities between July 30, 2024 and January 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2025.  CASE DETAILS:  According to the Complaint, Intellia made false and misleading statements to the mar ...

LOS ANGELES, April 14, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ: NTLA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between July 30, 2024 and January 8, 2025, inclusive (the "Class P ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Intellia Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's drug development programs [2][4]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses exceeding $50,000 in Intellia between July 30, 2024, and January 8, 2025, to discuss their legal rights [1]. - There is an April 14, 2025, deadline for investors to seek the role of lead plaintiff in a federal securities class action against Intellia [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3]. Group 2: Company Developments and Financial Impact - Intellia's complaint alleges that the company and its executives made false statements regarding the Phase 1/2 study of NTLA-3001 for treating alpha-1 antitrypsin deficiency-associated lung disease [4]. - On January 9, 2025, Intellia announced a strategic shift, focusing on drug candidates NTLA-2002 and nex-z, while discontinuing NTLA-3001, leading to a workforce reduction of approximately 27% [5]. - Following this announcement, Intellia's stock price fell by $1.82 per share, or 15.14%, closing at $10.20 per share on January 10, 2025 [6].

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit from investors who purchased securities during a specified period, alleging misleading statements regarding the viability of its drug development programs [1][4]. Company Overview - Intellia is a genome editing company focused on developing curative therapeutics, with a notable project being NTLA-3001 for treating alpha-1 antitrypsin deficiency-associated lung disease [3]. Allegations in the Lawsuit - The lawsuit claims that Intellia's management made false or misleading statements about the viability and development of NTLA-3001, including: - Misrepresentation of reliable information regarding NTLA-3001's development and marketing potential [4]. - Overly optimistic timelines for dosing and future studies that did not align with reality [4]. - Lack of capability to timely dose patients or maintain research and development for NTLA-3001 due to the challenges of viral-based editing methods [4]. - Concerns about the cost and inefficiency of viral-based editing drugs, even if NTLA-3001 was successful [4]. Impact of Company Reorganization - On January 9, 2025, Intellia announced a reorganization, prioritizing resources towards NTLA-2002 and nex-z, leading to the discontinuation of NTLA-3001. This announcement resulted in a stock price drop of over 15% [5].